PSCH - ETF AI Analysis
Top Page
Invesco S&P SmallCap Health Care ETF (PSCH)
Rating:66Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating solid momentum in its small-cap health care holdings.
Top Holdings Showing Solid Gains
Many of the largest positions, including several biotech and health care names, have delivered strong year-to-date performance, helping drive the fund’s returns.
Focused Exposure to U.S. Health Care
The fund is heavily invested in U.S. health care companies, giving investors targeted exposure to a sector with steady long-term demand.
Negative Factors
Sector Concentration Risk
With most assets in health care, the ETF is vulnerable if this single sector faces regulatory changes, reimbursement pressure, or other industry-specific challenges.
Limited Geographic Diversification
Almost all holdings are U.S.-based, so investors get little protection if the U.S. market or economy experiences a downturn.
Small-Cap Volatility
Because the fund focuses on small-cap companies, its share price can be more volatile and sensitive to market swings than large-cap or more diversified ETFs.
PSCH vs. SPDR S&P 500 ETF (SPY)
AUM183.99M
RegionNorth America
Expense Ratio0.29%
Beta0.81
IssuerInvesco
Inception DateApr 07, 2010
Dividend Yield0.04%
Asset ClassEquity
Index TrackedS&P SmallCap 600 Capped Health Care Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume20,049
30 Day Avg. Volume26,993
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
67.33Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering70
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSCH Summary
PSCH is an ETF that focuses on smaller U.S. health care companies by following the S&P SmallCap 600 Capped Health Care Index. It owns a mix of businesses in areas like drugs, biotech, medical devices, and health care services. Well-known holdings include Molina Healthcare and Teleflex. Investors might consider PSCH if they want growth potential from newer, more agile health care companies while still spreading their money across many stocks. A key risk is that small health care companies can be very volatile, so the ETF’s price can move up and down sharply with changes in the market and the health care sector.
How much will it cost me?The Invesco S&P SmallCap Health Care ETF (PSCH) has an expense ratio of 0.29%, meaning you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average because the ETF focuses on a niche sector and tracks small-cap health care companies, which require more active management compared to broad-market passive ETFs.
What would affect this ETF?The Invesco S&P SmallCap Health Care ETF (PSCH) could benefit from advancements in biotechnology, pharmaceuticals, and medical devices, as small-cap companies often drive innovation in the health care sector. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, and regulatory changes in the U.S. health care industry that could impact profitability. The ETF’s focus on U.S. small-cap health care stocks makes it sensitive to domestic economic conditions and sector-specific trends.
PSCH Top 10 Holdings
PSCH is essentially a small-cap health care laboratory, with biotech names like Corcept Therapeutics, Glaukos, and Protagonist Therapeutics doing most of the heavy lifting as they’ve been rising steadily this year. Alkermes and TG Therapeutics add more biotech firepower, though their recent trading has been a bit more mixed, occasionally losing steam and tempering the fund’s momentum. With almost all exposure in U.S. health care and a clear tilt toward smaller, innovation-driven drug and device makers, performance is tightly tied to the fortunes of a handful of fast-moving, research-focused companies.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 5.66% | $10.13M | $12.19B | 54.78% | 76 Outperform | |
| Glaukos | 5.16% | $9.23M | $9.87B | 102.09% | 61 Neutral | |
| Protagonist Therapeutics | 4.70% | $8.42M | $9.59B | 151.75% | 68 Neutral | |
| Alkermes | 4.02% | $7.20M | $7.71B | 70.45% | 80 Outperform | |
| TG Therapeutics | 3.73% | $6.68M | $8.25B | 67.57% | 65 Neutral | |
| Teleflex | 3.05% | $5.45M | $5.55B | 0.52% | 68 Neutral | |
| Ligand Pharma | 3.00% | $5.36M | $5.67B | 71.62% | 60 Neutral | |
| PTC Therapeutics | 2.88% | $5.15M | $5.51B | 8.14% | 72 Outperform | |
| Radnet | 2.81% | $5.02M | $5.94B | 2.00% | 63 Neutral | |
| Merit Medical Systems | 2.71% | $4.84M | $5.16B | 0.97% | 68 Neutral |
PSCH Technical Analysis
Neutral
―
Price Trends
54.19
Negative
50.59
Positive
47.08
Positive
Market Momentum
-0.32
Positive
38.73
Neutral
16.54
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSCH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 54.52, equal to the 50-day MA of 54.19, and equal to the 200-day MA of 47.08, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 38.73 is Neutral, neither overbought nor oversold. The STOCH value of 16.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PSCH.
PSCH Peer Comparison
Comparison Results
Performance Comparison
PSCH
Invesco S&P SmallCap Health Care ETF
53.13
12.53
30.86%
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents